Theravance Biopharma, Inc. (TBPH) Forms $28.44 Double Bottom; Shorts at Curis (CRIS) Lowered By 7.83%

February 13, 2018 - By rebbecca

Curis Incorporated (NASDAQ:CRIS) had a decrease of 7.83% in short interest. CRIS’s SI was 1.95M shares in February as released by FINRA. Its down 7.83% from 2.11 million shares previously. With 2.10M avg volume, 1 days are for Curis Incorporated (NASDAQ:CRIS)’s short sellers to cover CRIS’s short positions. The SI to Curis Incorporated’s float is 1.72%. The stock increased 6.21% or $0.0322 during the last trading session, reaching $0.5508. About 1.03M shares traded. Curis, Inc. (NASDAQ:CRIS) has risen 2.47% since February 13, 2017 and is uptrending. It has underperformed by 14.23% the S&P500.

Theravance Biopharma, Inc. (TBPH) formed double bottom with $27.30 target or 4.00% below today’s $28.44 share price. Theravance Biopharma, Inc. (TBPH) has $1.54B valuation. The stock increased 1.75% or $0.49 during the last trading session, reaching $28.44. About 180,864 shares traded. Theravance Biopharma, Inc. (NASDAQ:TBPH) has risen 89.85% since February 13, 2017 and is uptrending. It has outperformed by 73.15% the S&P500.

Among 8 analysts covering Theravance Biopharma (NASDAQ:TBPH), 7 have Buy rating, 1 Sell and 0 Hold. Therefore 88% are positive. Theravance Biopharma had 20 analyst reports since August 12, 2015 according to SRatingsIntel. The stock of Theravance Biopharma, Inc. (NASDAQ:TBPH) has “Outperform” rating given on Thursday, February 8 by Leerink Swann. Robert W. Baird downgraded the stock to “Underperform” rating in Wednesday, October 12 report. Needham maintained the shares of TBPH in report on Friday, September 15 with “Buy” rating. The stock of Theravance Biopharma, Inc. (NASDAQ:TBPH) has “Neutral” rating given on Wednesday, August 12 by Robert W. Baird. As per Monday, October 30, the company rating was maintained by Robert W. Baird. The firm has “Buy” rating given on Tuesday, November 7 by Cantor Fitzgerald. The stock has “Buy” rating by Guggenheim on Monday, June 20. Needham maintained Theravance Biopharma, Inc. (NASDAQ:TBPH) rating on Wednesday, November 8. Needham has “Buy” rating and $45.0 target. The stock of Theravance Biopharma, Inc. (NASDAQ:TBPH) earned “Buy” rating by Needham on Wednesday, December 21. The firm earned “Buy” rating on Wednesday, August 2 by Needham.

Analysts await Theravance Biopharma, Inc. (NASDAQ:TBPH) to report earnings on February, 26. They expect $-1.15 EPS, up 15.44% or $0.21 from last year’s $-1.36 per share. After $-1.27 actual EPS reported by Theravance Biopharma, Inc. for the previous quarter, Wall Street now forecasts -9.45% EPS growth.

Investors sentiment decreased to 1.32 in 2017 Q3. Its down 0.46, from 1.78 in 2017Q2. It dropped, as 13 investors sold Theravance Biopharma, Inc. shares while 18 reduced holdings. 7 funds opened positions while 34 raised stakes. 35.46 million shares or 3.52% more from 34.25 million shares in 2017Q2 were reported. Moneta Group Invest Limited Liability Co has 8,742 shares for 0.05% of their portfolio. Wells Fargo Communication Mn has 0% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 117,079 shares. Foundation Asset Mngmt Lp has invested 4.61% in Theravance Biopharma, Inc. (NASDAQ:TBPH). State Street Corp has 913,836 shares. Ny State Common Retirement Fund invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Price T Rowe Assocs Md accumulated 2.30 million shares or 0.01% of the stock. Envestnet Asset Mgmt stated it has 297 shares. D E Shaw & accumulated 90,848 shares or 0% of the stock. 2,500 were reported by Qs Invsts Ltd Liability Corp. Ameritas Invest stated it has 3,865 shares. Rhumbline Advisers owns 46,318 shares for 0% of their portfolio. Swiss Fincl Bank reported 71,342 shares. Sg Americas Secs Llc accumulated 0% or 9,061 shares. Amer Century invested in 0% or 28,279 shares. Nationwide Fund Advsr has 0% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH).

Since September 6, 2017, it had 0 insider buys, and 1 insider sale for $451,350 activity. Shafer Bradford J had sold 14,670 shares worth $451,350 on Wednesday, September 6.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company has market cap of $90.32 million. The firm develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It currently has negative earnings. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis.